In June 2010 DiaMedica Acquired Sanomune

DiaMedica: a merger of two of Canada’s Top 10™ life science companies
 

• DiaMedica has been focused on a novel approach to treating type 2 diabetes.
• Approach resulted in 3 successful phase II clinical trials
• Supported by two past presidents of the American Diabetes Association
• Selected as a Top 10™ Life Science Company in Canada in 2007/2008 and 2008/2009

• Sanomune was focused on Neurological diseases – initially Alzheimer’s
• Showed protection and proliferation of neural cells (brain cells)
• Selected as a Top 10™ Life Science Company in Canada in 2008/2009